You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
3 August 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials, su...
3 August 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, announced on Monday that the US Food and Drug Administration (FDA) has granted Orphan Drug D...
3 August 2026 - Biopharmaceutical company Biocon Limited (BSE:532523) (NSE:BIOCON) announced on Monday the US commercial launch of Yesafili (aflibercept-jbvf), an FDA-approved interchangeable biosimilar to Eylea 2 mg.The VEGF inhibitor is indicated f...
3 August 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) on Monday announced a peer-reviewed study demonstrating the use of its Parsortix platform to detect antibody-drug conjugate (ADC)-relevant targets on circulating tumour cells (CTCs...
3 August 2026 - Swedish pharmaceutical company Immedica, backed by investment firms KKR & Co Inc (NYSE:KKR) and Impilo, announced on Monday that Qatar's Ministry of Public Health has approved Zepzelca (lurbinectedin) in combination with atez...
3 August 2026 - Coiled Therapeutics plc (AIM: COIL) (OTCQB: COTXF), a clinical-stage precision oncology company, announced on Monday that it has dosed the first patient in the US with an optimised lipid-based oral formulation of its Phase I cancer th...
3 August 2026 - Clinical-stage biopharmaceutical company Mezzion Pharma Co Ltd on Sunday announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disea...